Developer docs
API playgroundTry for free, no card

Search company profiles

Akshay Patel

Full company profile

uuid0045h4y

Namestring
Akshay Patel
Company typeenum
Private
Founded yearstring
-
Descriptiontext

The entity named "Akshay Patel" appears in the source data as a 5-employee firmographic record based in Morganville, New Jersey, with a listed website URL pointing to ClinicalTrials.gov. However, the underlying source material explicitly clarifies that the aggregated content pertains to ClinicalTrials.gov — a US government clinical trial registry maintained by the National Library of Medicine (NLM), part of the National Institutes of Health — not to a company by the name of Akshay Patel. As a result, no products, services, revenue model, customer base, technology stack, or go-to-market mechanics can be reliably attributed to the named entity from the provided data. The most plausible interpretation, given the ClinicalTrials.gov association and a 5-employee headcount, is that "Akshay Patel" refers to an individual investigator or registered user profile on the public registry rather than an operating commercial company. No pricing, distribution, marketing, partnership, or certification data is available. No technology stack, AI capabilities, app presence, or integration footprint is documented. Investment analysis on this entity cannot proceed beyond noting the firmographic mismatch and the absence of substantive company-level information.

Short descriptiontext

Akshay Patel appears to be a 5-employee entity registered in Morganville, New Jersey, with a firmographic link to ClinicalTrials.gov that does not correspond to an identifiable operating company. The source data contains no information about a company under this name.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
Markets served

Serves global market

Keyword5 values
insufficient data, entity not identified, no offering evidence, source mismatch, unknown company
Product category
Unidentified
Social media profiles1 record
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

No core offering can be determined. The source material describes ClinicalTrials.gov, a U.S. government clinical trial registry, and does not describe products or services attributable to an entity named Akshay Patel.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat1 record

Each record includes

Type, Details

Customer concentration

Classification, Details

No data
Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Akshay Patel

Unidentifiedclinicaltrials.gov

Akshay Patel appears to be a 5-employee entity registered in Morganville, New Jersey, with a firmographic link to ClinicalTrials.gov that does not correspond to an identifiable operating company. The source data contains no information about a company under this name.

What Akshay Patel does

The entity named "Akshay Patel" appears in the source data as a 5-employee firmographic record based in Morganville, New Jersey, with a listed website URL pointing to ClinicalTrials.gov. However, the underlying source material explicitly clarifies that the aggregated content pertains to ClinicalTrials.gov — a US government clinical trial registry maintained by the National Library of Medicine (NLM), part of the National Institutes of Health — not to a company by the name of Akshay Patel. As a result, no products, services, revenue model, customer base, technology stack, or go-to-market mechanics can be reliably attributed to the named entity from the provided data. The most plausible interpretation, given the ClinicalTrials.gov association and a 5-employee headcount, is that "Akshay Patel" refers to an individual investigator or registered user profile on the public registry rather than an operating commercial company. No pricing, distribution, marketing, partnership, or certification data is available. No technology stack, AI capabilities, app presence, or integration footprint is documented. Investment analysis on this entity cannot proceed beyond noting the firmographic mismatch and the absence of substantive company-level information.

Akshay Patel firmographics

Firmographics
Name
Akshay Patel
Website
https://clinicaltrials.gov
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
Akshay Patel appears to be a 5-employee entity registered in Morganville, New Jersey, with a firmographic link to ClinicalTrials.gov that does not correspond to an identifiable operating company. The source data contains no information about a company under this name.
Ownership category
akta.pro rank

Akshay Patel business model

Business model
GTM type
B2C
Offering type
Services

Akshay Patel product offering

Product offering

Core offering

No core offering can be determined. The source material describes ClinicalTrials.gov, a U.S. government clinical trial registry, and does not describe products or services attributable to an entity named Akshay Patel.

Differentiator

Problem solved

Functional benefit

Akshay Patel technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Akshay Patel partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights5 records

Akshay Patel competitors and assessment

Company assessment

Market position

Competitive moat1 record

Customer concentration

Akshay Patel social profiles

Digital presence

Akshay Patel financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Akshay Patel leadership team

Management profile

Number of profiles

Akshay Patel funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Akshay Patel M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akshay Patel

What does Akshay Patel do?

No core offering can be determined. The source material describes ClinicalTrials.gov, a U.S. government clinical trial registry, and does not describe products or services attributable to an entity named Akshay Patel.

When was Akshay Patel founded?

Akshay Patel was founded in -1. It employs 1 to 10 people.

Does Akshay Patel have an API?

No public API is recorded for Akshay Patel.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessLineStudy finds disparities in cancer research in India since 2001 despite economic growthA study published in the journal 'CANCER' reveals that India experienced inconsistent growth in cancer clinical research between 2001 and 2020 despite strong economic development. The analysis of data from World Bank and ClinicalTrials.gov indicates that while low- and middle-income countries saw an overall increase in trials, nations like India, Thailand, and Vietnam did not develop independent high-complexity research capabilities comparable to China or South Korea.ClinicaltrialsClinicalTrials.govThe article provides a comprehensive glossary of terminology used on ClinicalTrials.gov, defining key concepts related to clinical study design, participant eligibility, and regulatory reporting. It details specific definitions for terms such as adverse events, intervention arms, and compliance violations under the Food and Drug Administration Amendments Act of 2007. The content serves as an informational reference for understanding how clinical trials are registered and reported.CellA comprehensive survey of the clinical trial Landscape on digital therapeuticsA study reviewed 280 completed digital therapeutics clinical trials registered on ClinicalTrials.gov as of August 8, 2023, finding 50.4% treated disease, 42.9% managed disease, and 6.8% improved health function. Randomized controlled trials made up 67.5% of completed studies, with 36 (12.9%) involving marketed products. The authors call for harmonized global classification and standardized protocols.National Center for Biotechnology InformationCosts of Drug Development and Research and Development Intensity in the US, 2000-2018An economic evaluation study estimated drug development costs in the US from 2000 to 2018 using public and proprietary data sources including ClinicalTrials.gov, FDA internal databases, Medidata and IQVIA's GrantPlan. It calculated three measures: mean cash outlay, expected cost accounting for failure probabilities, and expected capitalized cost using an 11.0% real cost of capital.National Center for Biotechnology InformationGlobal trends in clinical trials and interventions for the metabolic syndrome: A comprehensive analysis of the WHO International Clinical Trials platformA study analysed clinical trials registered on the WHO International Clinical Trials Registry Platform from 1999 to 18 April 2023, finding 2,379 unique studies across 18 registries, with ClinicalTrials.gov accounting for 55.19%. Diet and exercise interventions were most common, followed by metformin and statins, while trials focused on lipid profiles, insulin and blood pressure rather than body mass. The authors call for more rigorously designed treatment trials.National Center for Biotechnology InformationAdaptive design clinical trials: current status by disease and trial phase in various perspectivesA study analyzed clinical trials registered on ClinicalTrials.gov from January 2006 to July 2021 using FDA adaptive design keywords, identifying 267 trials, of which 236 actually employed adaptive designs. Adaptive treatment selection was most common (110 of 292 designs), followed by seamless phase and group sequential designs, with phase 2 trials and oncology indications most frequent. The authors also examined COVID-19 trials, where adaptive platform design was used in 9 of 16 trials.HHS.govNIH-Funded Clinical Trials Reported to ClinicalTrials.govThe NIH announced an audit to determine whether its intramural and extramural clinical trials complied with federal reporting requirements, requiring awardees to submit results within one year of the earlier of the estimated or completion date. NIH must post results on ClinicalTrials.gov within 30 days of receipt. The audit was assigned to the Office of Audit Services, with report numbers W-00-21-51020 and A-06-21-07000, expected in FY2022.